Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects

Lemtrada Stroke Lawsuit News

It will not be long before advanced multiple sclerosis patients will get to try stem-cell therapy before considering Lemtrada

Thursday, November 19, 2020 - People suffering from a form of multiple sclerosis now have another option to treat their condition rather than risk the life-threatening side effects associated with taking Lemtrada. Multiple Sclerosis News Today (MSNT) reports that a Swedish study has concluded that a simple stem-cell injection can affectively halt some of the symptoms of relapse-remitting multiple sclerosis RRMS). Researchers stated that RRMS patients in the late stages of the disease should weigh the risks of the known side effects of Stem Cell Therapy with the unpredictable side effects of Lemtrada. Lemtrada is to be taken by RRMS patients only when all other disease-modifying therapies have been tried and failed. One would assume the list to include Stem Cell Therapy once it is formally approved. Lemtrada infusions must be given in a hospital with available emergency room personnel and equipment as reports of patients experiencing a stroke or heart attack immediately or within 72 hours have been made. If you or a loved one have experienced a stroke or heart attack after taking Lemtrada, Lemtrada lawsuit lawyers offer a free consultation and no obligation to file a claim.

Multiple Sclerosis News Today writes, " An autologous hematopoietic stem cell transplant (AHSCT) is more effective than Lemtrada (alemtuzumab) at achieving no evidence of disease activity and preventing relapses in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study in Sweden reported." Stem Cell transplantation is a one-time treatment and carries some early and potentially life-threatening side effects but after three months the patient is mostly in the clear. "AHSCT is an intensive, experimental way of treating MS that is meant to rebuild a patient's immune system to stop attacks on the brain and spinal cord," MSNT writes.

Even though Stem Cell Transplantation may be more effective in the long-run than traditional disease-modifying therapies like Lemtrada, RRMS patients may experience difficult side effects in the early stages of Stem Cell Transplantation and could potentially reject the transplant. First, the patient's existing immune system must be ablated with chemotherapy to prepare it to accept the new cells with a minimum of rejection. During the time of having a weakened immune system, the patient is at risk of getting sick and being unable to fight off an infection or disease. Chemotherapy toxicity may be light, however, because the patient is the stem cell donor, taken from their bone marrow harvested from the broad hip bone, and not taken from a foreign donor. The Sweedish Stem Cell Therapy study concluded that SCT patients had a significantly lower relapse rate than those who were given Lemtrada, and nearly double the number of patients that were free of additional MRI events such as brain lesions. Patients given SCT also showed a decrease in the progression of the disease according to the study published in the Journal of Neurology, Neurosurgery, and Psychiatry.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.